Studying cell communication in hairy cell leukemia for better care
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how cells talk to each other in hairy cell leukemia, a rare blood cancer. It aims to find ways to improve patient care. Participants may be asked to give blood or tissue samples for research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years or older
- Must have a confirmed diagnosis of hairy cell leukemia
- Must sign a consent form agreeing to take part
- Healthy donors should be in good general health
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny particles called extracellular vesicles in the blood of people with Hairy Cell Leukemia. Researchers want to understand if these particles can help improve how the disease is managed and followed.
This study collects human samples (like blood or other specimens) to learn more about hairy cell leukemia and other leukemias. It also helps researchers develop new lab-made immune-based medicines for cancer treatment.
This study uses advanced 3D lab models to test personalized treatments for certain types of blood cancer (CLL, SMZL, HCL). It aims to find better ways to use immunotherapy and combination therapies for each patient.
This study watches the course of hairy cell leukemia (HCL) in different phases—when first diagnosed, after it comes back, or long after successful treatment. The goal is to better understand the disease and plan future care.
This trial studies the best way to treat hairy cell leukemia and checks how well the approach works in people who need treatment for their disease. It may help if you have classic hairy cell leukemia and have not had certain prior chemotherapy.
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
Hear when a new Hairy Cell Leukemia (HCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.